NeuroSense Therapeutics (NeuroSense Therapeutics) Dividends per Share : $0.00 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NeuroSense Therapeutics Dividends per Share?

NeuroSense Therapeutics's dividends per share for the three months ended in Dec. 2023 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Its Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00. As of today, NeuroSense Therapeutics's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

NeuroSense Therapeutics Dividends per Share Historical Data

The historical data trend for NeuroSense Therapeutics's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroSense Therapeutics Dividends per Share Chart

NeuroSense Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dividends per Share

NeuroSense Therapeutics Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Dividends per Share	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of NeuroSense Therapeutics's Dividends per Share

For the Biotechnology subindustry, NeuroSense Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroSense Therapeutics's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where NeuroSense Therapeutics's Dividend Yield % falls into.

NeuroSense Therapeutics Dividends per Share Calculation

Dividends paid to per common share.

NeuroSense Therapeutics (NAS:NRSN) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

NeuroSense Therapeutics's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.16
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

NeuroSense Therapeutics Dividends per Share Related Terms

Thank you for viewing the detailed overview of NeuroSense Therapeutics's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroSense Therapeutics (NeuroSense Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroSense Therapeutics Ltd (NAS:NRSN) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 HaMenofim Street, Building B, Herzliya, ISR, 4676670

Website

https://www.neurosense-tx.com

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.